TLX Investors Get Chance to Lead Securities Fraud Suit Against Telix Pharma

The Schall Law Firm has issued a fresh call to investors of Telix Pharmaceuticals Limited (“Telix” or “the Company,” NASDAQ: TLX) who bought shares between February 21, 2025 and August 28, 2025 to step forward before January 9, 2026 to participate in a class‑action lawsuit. The lawsuit claims that Telix misled the market by overstating progress on its prostate cancer therapeutic candidates and overstating the integrity of its supply chain. As a result, Telix’s public statements during the “Class Period” were allegedly “false and materially misleading,” leading to investor losses once the truth emerged. This case has not yet been certified — meaning investors are not yet represented by an attorney — but those who choose not to participate may remain “absent class members.” Anyone who believes they suffered a loss is encouraged to contact Schall Law for a free evaluation. #Telix #TLX #SecuritiesFraud #ClassAction #SlimScan #GrowthStocks #CANSLIM